A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing pharmacokinetic data and modeling approaches without systematic review methodology.
PubMed 40330819 · doi:10.2147/DDDT.S506957
What was done
The authors reviewed the pharmacokinetics, pharmacokinetic drug-drug interactions (DDIs), and pharmacokinetic modeling strategies for four approved GLP-1 receptor agonists (exenatide, liraglutide, dulaglutide, semaglutide) and one dual GLP-1/GIP receptor agonist (tirzepatide). They evaluated structural modifications extending half-life, mechanisms of interaction, and 30 predictive pharmacokinetic models.
What was found
Native human GLP-1 has a half-life of 2 minutes, whereas approved analogues achieve prolonged half-lives via amino acid substitutions, fatty acid conjugation, or albumin/Fc fusion. Clinically significant drug-metabolizing enzyme- and transporter-mediated DDIs were not identified. Interaction mechanisms are primarily restricted to delayed gastric emptying; while mostly clinically insignificant, significant changes in exposure were noted for oral contraceptives (with tirzepatide) and levothyroxine (with oral semaglutide). The abstract reports no quantitative values for pharmacokinetic parameters or interaction magnitudes.
Why it matters
This review outlines the clinical pharmacology of widely prescribed incretin mimetics and highlights key co-administered medications, specifically oral contraceptives and levothyroxine, that require therapeutic monitoring due to delayed gastric emptying.
Limits
As a narrative review, it lacks a systematic search protocol and risk-of-bias evaluation. The abstract does not provide exact effect sizes, participant numbers, or quantitative parameters. Interactions mediated by physiological changes such as reduced fat mass, altered cytochrome P450 activity, and glomerular filtration rate shifts remain poorly understood.
Cited by
- supports Endogenous human GLP-1 has a half-life of only a few minutes, whereas semaglutide was molecularly modified to have a half-life of approximately 5 to 7 days.